Ginkgo Bioworks Holdings, Inc. (DNA)

14.54 -0.58 (-3.84%)

As of 2025-10-16 20:26:12 EST

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.

Traded asNYSE: DNA
ISINUS37611X2099
CIK0001830214
LEI—
EIN872652913
SectorBiotechnology
IndustryBiological Products, (No Diagnostic Substances)
CEOJason Kelly
Employees834
Fiscal Year End1231
Address27 DRYDOCK AVENUE, BOSTON, MA, 02210
Phone(877) 442-5362
Websitehttp://ginkgobioworks.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
DNAGinkgo Bioworks Holdings, Inc.2025-10-16 20:26:1214.54-0.58-3.84
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
DNA0001830214Ginkgo Bioworks Holdings, Inc.US37611X2099—872652913NYSE2836Biological Products, (No Diagnostic Substances)1231DE27 DRYDOCK AVENUEBOSTONMA02210UNITED STATESUS(877) 442-536227 DRYDOCK AVENUE, BOSTON, MA, 0221027 DRYDOCK AVENUE, BOSTON, MA, 02210Soaring Eagle Acquisition Corp.Biotechnology2008Jason Kelly834http://ginkgobioworks.com617,000,00058,819,522—Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.2025-10-10 21:23:48
This is a preview of the latest data. Subscribe to access the full data.
DNA Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
DNA Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2024617,000,000-1,816,000,000-74.6404———
20232,433,000,00041,000,0001.714———
20222,392,000,0002,141,500,000854.8902———
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Mark DmytrukChief Financial Officer2024460,000—1,320,000—01,780,000
Reshma ShettyChief Operating Officer, President2024250,000—0—01,231,000
Jason KellyChief Executive Officer2024250,000—0—01,231,000
Jason KellyChief Executive Officer2023250,000—0—12,500262,500
Mark DmytrukChief Financial Officer2023460,000—1,218,000—16,5001,694,500
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2024834
20231,218
20221,292
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue227,043,000251,455,000477,706,000
Cost Of Revenue38,549,0007,481,000204,216,000
Gross Profit———
Research And Development Expenses424,061,000580,621,0001,052,643,000
General And Administrative Expenses246,161,000385,025,0001,429,799,000
Operating Expenses786,800,0001,115,861,0002,686,658,000
Operating Income-559,757,000-864,406,000-2,208,952,000
Net Income-547,029,000-892,869,000-2,104,929,000
Earnings Per Share Basic-10.54-0.46-1.25
Earnings Per Share Diluted-10.54-0.46-1.25
Weighted Average Shares Outstanding Basic51,894,6391,944,420,0001,679,061,465
Weighted Average Shares Outstanding Diluted51,894,6391,944,420,0001,679,838,849
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents561,572,000944,073,0001,315,792,000
Marketable Securities Current———
Accounts Receivable586,000742,00080,907,000
Inventories—46,0004,364,000
Non Trade Receivables—1,546,0001,561,000
Other Assets Current—362,000487,000
Total Assets Current602,744,0001,001,749,0001,450,079,000
Marketable Securities Non Current———
Property Plant And Equipment203,720,000188,193,000314,773,000
Other Assets Non Current55,336,00058,055,00088,725,000
Total Assets Non Current774,705,000663,593,0001,089,242,000
Total Assets1,377,449,0001,665,342,0002,539,321,000
Accounts Payable14,169,0009,323,00010,451,000
Deferred Revenue27,710,00044,486,00047,817,000
Short Term Debt———
Other Liabilities Current——114,694,000
Total Liabilities Current107,266,000163,860,000172,962,000
Long Term Debt———
Other Liabilities Non Current16,576,00018,733,00031,191,000
Total Liabilities Non Current554,125,000404,330,000630,082,000
Total Liabilities661,391,000568,190,000803,044,000
Common Stock5,000199,000190,000
Retained Earnings-5,837,557,000-5,290,528,000-4,397,659,000
Accumulated Other Comprehensive Income-1,806,0001,484,000-2,632,000
Total Shareholders Equity716,058,0001,097,152,0001,736,277,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization63,020,00070,507,00042,552,000
Share Based Compensation Expense112,344,000229,884,0001,930,641,000
Other Non Cash Income Expense-1,224,000-2,147,000-183,000
Change In Accounts Receivable4,725,000-50,068,000-55,024,000
Change In Inventories——-164,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable4,771,000-1,183,000-10,844,000
Change In Other Liabilities———
Cash From Operating Activities-319,585,000-295,500,000-252,198,000
Purchases Of Marketable Securities———
Sales Of Marketable Securities4,519,000——
Acquisition Of Property Plant And Equipment62,541,00040,801,00052,271,000
Acquisition Of Business5,400,0000-82,367,000
Other Investing Activities-538,000990,000439,000
Cash From Investing Activities-62,236,000-80,693,000-67,394,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock———
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt—200,000200,000
Other Financing Activities———
Cash From Financing Activities-1,739,000-3,216,00095,337,000
Change In Cash-383,841,000-379,997,000-223,347,000
Cash At End Of Period561,572,000944,073,0001,315,792,000
Income Taxes Paid894,000670,0000
Interest Paid32,00083,00092,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share-10.54-0.46-1.25
Price To Earnings Ratio-0.9317-146.9565-54.08
Earnings Growth Rate2,191.3043-63.2-7.4074
Price Earnings To Growth Ratio-0.00042.32537.3008
Book Value Per Share13.79830.56431.0341
Price To Book Ratio0.7117119.803665.3724
Ebitda-483,021,000-821,599,000-2,062,271,000
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures78,547,000-56,073,000211,555,000
Free Cash Flow-398,132,000-239,427,000-463,753,000
Return On Equity-0.7639-0.8138-1.2123
One Year Beta2.9883.17522.5033
Three Year Beta2.70222.45852.2775
Five Year Beta2.53052.45852.2775
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Coen Steven P.—2025-10-015,609D5,503
HENRY CHRISTIAN ODirector2025-09-0910,000D24,310
HENRY CHRISTIAN ODirector2025-09-0810,000D34,310
Coen Steven P.—2025-08-22310D11,112
Coen Steven P.—2025-08-21587A11,266
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Capital Advisors, Ltd. LLC2025-09-3019,0001,28214.8206
CWM, LLC2025-09-30160,00010,94914.6132
Inspire Investing, LLC2025-09-30460,39331,57714.58
Green Alpha Advisors, LLC2025-09-30188,79612,94914.58
Farther Finance Advisors, LLC2025-09-3010,41071414.5798
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
ETF Series Solutions2025-07-31US Vegan Climate ETFVEGN12,786168,008.040.1393
INVESCO EXCHANGE-TRADED FUND TRUST2025-07-31Invesco RAFI US 1500 Small-Mid ETFPRFZ137,3161,804,332.240.0761
Global X Funds2025-07-31Global X Russell 2000 ETFRSSL19,690258,726.60.0197
FIDELITY CONCORD STREET TRUST2025-07-31Fidelity ZERO Total Market Index FundFZROX18,304240,514.560.0008
FIDELITY CONCORD STREET TRUST2025-07-31Fidelity ZERO Extended Market Index FundFZIPX11,910156,497.40.0086
This is a preview of the latest data. Subscribe to access the full data.